VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits B chronic lymphocytic leukemia cell migration

Blood

Volumn 115, Issue 4, 2010, Pages 846-849

  Ugarte Berzal, Estefanía ^a   Redondo Muñoz, Javier ^a   Eroles, Pilar ^b   Del Cerro, Mercedes Hernández ^a   García Marco, José A ^c   Terol, María José ^b   García Pardo, Angeles ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GELATIN; GELATINASE B; MATRIGEL; STAT1 PROTEIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; SMALL INTERFERING RNA; STAT1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; CELL EXPANSION; CELL MIGRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; UMBILICAL VEIN; ZYMOGRAPHY; B LYMPHOCYTE; CELL CULTURE; CELL MOTION; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

B-LYMPHOCYTES; CELL MOVEMENT; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MATRIX METALLOPROTEINASE 9; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 77949325941     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-239426     Document Type: Article

References (22)

1. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep. 2004;6(5):348-354. (Pubitemid 39214227)
2. Rai KR. Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. Exp Hematol. 2007;35(suppl 1):134-136. (Pubitemid 46427990)
3. Till KJ, Spiller DG, Harris RJ, et al. CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood. 2005;105(12):4813-4819.
4. Kamiguti AS, Lee ES, Till KJ, et al. The role of matrix metalloproteinase-9 in the pathogenesis of chronic lymphocytic leukemia. Br J Haematol. 2004;125(2):128-140. (Pubitemid 38534963)
5. Redondo-Muñoz J, Escobar-Díaz E, Samaniego R, et al. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 2006;108(9):3143-3151.
6. Redondo-Muñoz J, Terol MJ, García-Marco JA, García-Pardo A. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Blood. 2008;111(1):383-386.
7. Chen H, Treweeke AT, West DC, et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood. 2000;96(9):3181-3187.
8. Bauvois B, Dumont J, Mathiot C, Kolb JP. Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferons. Leukemia. 2002;16(5):791-798. (Pubitemid 34537550)
9. Redondo-Muñoz J, Ugarte-Berzal E, García-Marco JA, et al. alpha4beta1 integrin and 190 kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood. 2008;112(1):169-178.
10. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109(3):227-241. (Pubitemid 41337127)
11. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signaling: in control of vascular function. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
12. Eriksson A, Cao R, Pawliuk R, et al. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. Cancer Cell. 2002;1(1):99-108. (Pubitemid 41039180)
13. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59):1-11.
14. Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem. 1998;41(14):2588-2603. (Pubitemid 28321908)
15. Bartoli M, Gu X, Tsai NT, et al. Vascular endothelial growth factor activates STAT proteins in aortic endothelial cells. J Biol Chem. 2000;275(43):33189-33192.
16. Lee YK, Shanafelt TD, Bone ND, et al. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT1 and 3: implication for apoptosis resistance. Leukemia. 2005;19(4):513-523.
17. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: critical role of STAT-1alpha1. J Immunol. 2001;167(9):5150-5559 (Pubitemid 33009751)
18. Nguyen J, Knapnougel P, Lesavre P, Bauvois B. Inhibition of matrix metalloproteinase-9 by interferons and TGF-beta1 through distinct signalings accounts for reduced monocyte invasiveness. FEBS Lett. 2005;579(25):5487-5493. (Pubitemid 41455619)
19. Ma Z, Chang MJ, Shah RC, Benveniste EN. Interferon-gamma-activated STAT-1alpha suppresses MMP-9 gene transcription by sequestration of the coactivators CBP/p300. J Leuk Biol. 2005;78(2):515-523. (Pubitemid 41061323)
20. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia. 2000;14(8):1414-1418. (Pubitemid 30599322)
21. Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000;96(2):768-770. (Pubitemid 30463404)
22. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia. 2005;19(4):524-530. (Pubitemid 40521154)